attitude towards Food consumption in AD patients Revive with RIVastigmine Effects
Not Applicable
- Conditions
- Alzheimer's disease (AD)
- Registration Number
- JPRN-UMIN000018172
- Lead Sponsor
- Kagawa University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who fall into any of the following criteria are excluded from this study: 1) Patients with a history of hypersensitivity to components of rivastigmine or to carbamate derivative 2) Patients with physical disabilities which interfere their food intake 3) Patients with life threating disease such as malignancy, pneumonia, etc. 4) Patients with a gastrointestinal disorder 5) Patients with conditions that are judged by physicians to be inappropriate to this study 6) Patients who need to start, or continue to use donepezil hydrochloride (drugs for dementia of Alzheimer type and Levy body), or galantamine hydrobromide (drug for dementia of Alzheimer type)
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Amount of meal actually eaten (average weight [%] of each meal eaten at each observation point)
- Secondary Outcome Measures
Name Time Method Following outcomes are evaluated for the amount of changes: 1. Time spend on lunch 2. Body weight 3. Scores of NPI-NH 4. Scores of MMSE